Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage

Leukemia and Lymphoma

Volumn 44, Issue 4, 2003, Pages 681-689

  Firer, Michael A ^a   Laptev, Raisa ^a   Kasatkin, Ilena ^a   Trombka, David ^b  

^a ARIEL UNIVERSITY   (Israel)

^b D Pharm Ltd   (Israel)

Author keywords

Cell surface antibody; Drug resistance; Ligand toxin; Multiple myeloma; Targeted drug delivery

Indexed keywords

CELL SURFACE PROTEIN; DINITROPHENYLHAPTEN; EPITOPE; IMMUNOGLOBULIN; RICIN A; TOXIN;

ANIMAL CELL; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL CLONE; CELL DESTRUCTION; CELL GROWTH; CELL KILLING; CELL LINEAGE; CELL SECRETION; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG TARGETING; ERYTHROLEUKEMIA CELL; FEMALE; FRIEND LEUKEMIA; GROWTH INHIBITION; HYBRIDOMA; HYBRIDOMA CELL CULTURE; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN CELL; TUMOR CELL;

ANIMALS; ANTIGENS; B-LYMPHOCYTES; CELL DIVISION; CELL LINE; CELL LINEAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EPITOPES; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; IMMUNOGLOBULINS; LEUKEMIA; LIGANDS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICROSCOPY, FLUORESCENCE; SPECIES SPECIFICITY; SPLEEN; TIME FACTORS; TOXINS, BIOLOGICAL;

EID: 0037375739     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000063381     Document Type: Review

References (34)

1. Nishida, K., Tamura, A., Nakazawa, N., Ueda, Y., Abe, T., Matsuda, F., et al. (1997) "The Ig heavy chain is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization", Blood 90, 526-534.
2. Drexler, H.G. and Matsuo, Y. (2000) "Malignant hematopoietic cell lines: in vitro models for the study of multiplemyeloma and plasma cell leukemia", Leukemia Research 24, 681-703.
3. Lockhurst, H.M., Sonneveld, P. and Verdonck, L.F. (1999) "Intensive treatment for multiple myeloma: where do we stand", Blood 106, 18-27.
4. Raje, N. and Anderson, K.C. (2000) "Introduction: the evolving role of bisphosphanate therapy in multiple myeloma", Blood 96, 381-383.
5. Smith, M.L. and Newland, A.C. (1999) "Treatment of myeloma", Quarterly Journal of Medicine 92, 4-11.
6. Morgan, G.J. (1999) "Advances in the biology and treatment of myeloma", British Journal of Hematology 105(Suppl. 1), 4-67.
7. Gadó, K., Domján, G., Hegyesi, H. and Falus, A. (2000) "Role of interleukin-6 in the pathogenesis of multiple myeloma", Cell Biology International 24, 195-209.
8. Kreitman, R. (2000) "Immunotoxins", Expert Opinion in Pharmacotherapy 1, 1117-1129.
9. Treon, S.P., Shima, Y., Grossbard, M.L., Preffer, F.I., Belch, A.R., Pilarski, L.M., et al. (2000) "Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy and induction of myeloma selective antigens", Annals of Oncology 11(Suppl. 1), 107-111.
10. Ohtomo, T., Sugamota, V., Ozoki, Y., Ono, K., Yoshimuro, Y., Kawai, S., et al. (1999) "Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells", Biochemical and Biophysical Research Communications 258, 583-591.
11. Vitetta, E.S., Thorpe, P.E. and Uhr, J.W. (1993) "Magic bullets or misguided missiles?", Immunology Today 14, 252-259.
12. Press, O.W., Martin, J.P., Thorpe, P.E. and Vitetta, E.S. (1998) "Ricin-A chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells", Journal of Immunology 141, 4410-4417.
13. Rihova, B. (1998) "Receptor-mediated targeted or toxin delivery", Advanced Drug Delivery Reviews 29, 273-289.
14. Kosmos, C., Stamatopolous, K., Belessi, C., Yataganas, X., Anagnostou, D. and Loukopoulos, A. (1998) "Somatic hypermutation of immunoglobulin variable region genes: focus on follicular lymphoma and multiple myeloma", Immunology Reviews 162, 281-292.
15. Bakkhus, M.H., Heirman, C., Van Riet, I., Van Camp, B. and Thielemans, K. (1992) "Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variations", Blood 80, 2326-2335.
16. Vescio, R.A., Cao, J., Hong, C.H., Lee, J.C., Wu, C.H., Der Danielian, M., et al. (1995) "Myeloma Ig heavy chain V region sequences reveal prior antigen selection and marked somatic mutation but no intraclonal variation", Journal of Immunology 155, 2487-2497.
17. Berenson, J.R., Vescio, R.A. and Said, I. (1998) "Multiple myeloma: the cells of origin - a two way street", Leukemia 12, 121-127.
18. Czerwinski, G., Tarasove, N. and Michejda, C.J. (1998) "Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug", Proceeding of the National Academy of Science, USA 95, 11520-11525.
19. Harris, A.L. (1990) "The epidermal growth factor receptor as a target for therapy", Cancer Cells 2, 321-323.
20. Pastan, I. and Fitzgerald, D. (1991) "Recombinant toxins for cancer treatment", Science 254, 1173-1177.
21. Davol, P.A., Bizuneh, A. and Frackelton, Jr., A.R. (1999) "Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo", Anticancer Research 19, 1705-1714.
22. McIntyre, G.D., Scott, C.F., Ritz, J., Bluttler, W.A. and Lambert, J.M. (1994) "Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents", Bioconjugate Chemistry 5, 88-97.
23. Volkman, D.J., Ahmad, A., Fauci, A.S. and Neville, D.M. (1982) "Selective abrogation of antigen specific human B cell responses by antigen-ricin conjugates", Journal of Experimental Medicine 156, 634-639.
24. Green, B.S., DeSouza, L.J., Arad-Yellin, R., Firer, M.A., Knossow, M. and Gigant, B. (1998) "Antibody-catalyzed reactions using novel haptens or designed substrates", The Immunologist 6(Suppl. 1), 119.
25. Gan, Y.H., Peng, S.Q. and Liu, H.Y. (2000) "Molecular mechanisms of apoptosis induced by ricin in HeLa cells", Acta Pharmacology (Singapore) 21, 243-248.
26. Hu, R., Zhai, Q., Liu, W. and Liu, X. (2001) "An insight into the mechanism of cytotoxicity of ricin to hepatoma cell: roles of Bcl-2 family proteins, caspases, Ca(2 + )-dependent proteases and protein kinase C", Journal of Cellular Biochemistry 81, 583-593.
27. Komatsu, N., Nakagawa, M., Oda, T. and Muramatsu, T. (2000) "Depletion of intracellular NAD + and ATP levels during ricin-induced apoptosis through the specific ribosomal inactivation results in the cytolysis of U937 cells", Journal of Biochemistry 128, 463-470.
28. Sandvig, K. and van Duers, B. (2000) "Entry of ricin and shiga toxin into cells: molecular mechanisms and medical perspectives", EMBO Journal 19, 5943-5950.
29. Geiseler, F. and Nubler, V. (1997) "Cellular resistance mechanisms with impact on the therapy of multiple myeloma", Leukemia 11(Suppl. 5), S1-S4.
30. Campone, M., Vavasseur, F., Le Cabellec, M.T., Meflah, K., Vallente, F.M. and Oliver, L. (2001) "Induction of chemoresistance in HL-60 cells concomitantly causes a resistance to apoptosis and the synthesis of P-glycoprotein", Leukemia 15, 1377-1387.
31. Aisenberg, A.C. and Bloch, K.J. (1972) "Immunoglobulins on the surface of neoplastic lymphocytes", New England Journal of Medicine 287, 272-276.
32. Sato, I., Abo, T., Onodera, S. and Kumagai, K. (1978) "Detection of monoclonal B lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins", Scandinavian Journal of Haematology 21, 433-444.
33. Ocqueteau, M., San Miguel, J.F., Gonzalez, M., Almeida, J. and Orfao, A. (1996) "Do myelomatous plasma cells really express surface immunoglobulins?", Haematologica 81, 460-463.
34. Thurnheer, C.M., Zuercher, A.W., Miescher, S.M., Rudolf, M.P., Vogel, M. and Stadler, B.M. (1999) "Molecular mimicry of the unidentified antigen of antibody IgE-ND", European Journal of Immunology 29, 2676-2683.